Edap Tms SA represents values of innovation, commitment, and excellence in the field of medical technology. As a global leader in therapeutic ultrasound, Edap Tms SA is dedicated to providing cutting-edge solutions for the treatment of urological conditions. With a strong corporate philosophy centered around patient care and continuous improvement, the company strives to deliver safe and effective medical devices that positively impact patients' lives. By combining advanced technology, scientific expertise, and a customer-centric approach, Edap Tms SA remains at the forefront of advancing minimally invasive therapies in the healthcare industry.

Edap Tms SA is primarily present in several countries and regions. These include the United States, Europe, Asia, and Latin America.

Some significant milestones that the company Edap Tms SA has achieved include: 1. In 2001, the company received FDA approval for their Ablatherm® High Intensity Focused Ultrasound (HIFU) system for the treatment of prostate cancer. 2. In 2015, Edap Tms SA announced the completion of a landmark study demonstrating the long-term efficacy and safety of their Ablatherm HIFU system. 3. In 2017, the company received FDA clearance for its Focal One® HIFU system, offering a non-invasive treatment option for localized prostate cancer. 4. Edap Tms SA has expanded its market presence globally, with installations of their HIFU systems in over 35 countries worldwide. 5. The company continues to innovate and develop new applications for their HIFU technology, driving advancements in minimally invasive treatments for various medical conditions.

Edap Tms SA is a leading global provider of innovative medical devices specializing in therapeutic ultrasound. Established in 1979, the company has a rich history of technological advancements in the field. Edap Tms SA's technology utilizes focused ultrasound waves to precisely treat a range of medical conditions, including urological and musculoskeletal disorders. With decades of experience, the company has earned a strong reputation for its cutting-edge solutions and commitment to improving patient outcomes. Edap Tms SA is dedicated to advancing non-invasive therapies and remains at the forefront of medical technology, consistently delivering groundbreaking solutions to healthcare professionals worldwide.

The main competitors of Edap Tms SA in the market include companies such as Intuitive Surgical Inc., Siemens AG, and SonaCare Medical LLC.

Edap Tms SA is primarily active in the medical technology industry.

The business model of Edap Tms SA revolves around providing innovative medical devices and solutions for the treatment of urology and other diseases. With a focus on High-Intensity Focused Ultrasound (HIFU) technology, Edap Tms SA aims to enhance patient care and offer non-invasive, personalized treatment options. By developing cutting-edge medical devices such as Ablatherm® and Focal One®, the company enables healthcare professionals to perform precise and targeted therapeutic procedures. Edap Tms SA's business model emphasizes continuous research and development to stay at the forefront of medical technology advancements, ultimately improving patient outcomes in urology and beyond.

De Edap Tms K/W is -10,38.

De Edap Tms KUV is 2,80.

De AlleAktien Kwaliteitsscore voor Edap Tms is 5/10.

De verwachte Edap Tms omzet is 68,12 mln. EUR.

De verwachte Edap Tms winst is -18,36 mln. EUR.

The company Edap Tms SA is a global provider of medical systems specializing in advanced medical technologies and products. They focus on two main areas: HIFU and Urology. HIFU stands for High-Intensity Focused Ultrasound and refers to the non-invasive treatment of tumors and other tissue abnormalities. The technology uses focused ultrasound energy to destroy tumor cells without damaging surrounding healthy tissue. Edap Tms SA offers a variety of HIFU systems, including Ablatherm® systems, which can be used for the treatment of prostate cancer as well as other medical conditions such as bladder, kidney, and liver tumors. The company also offers a wide range of urological solutions, including lithotripsy or stone removal technologies. These systems are frequently used by urologists for the removal of kidney stones and other urinary tract disorders. The lithotripsy technology works by using high-frequency sound waves to pulverize the stones into small pieces that can then be naturally passed out of the body. The company also offers other urological treatment solutions, including the "Sonolith i-move" technology, which allows doctors to be more flexible and adjust the device's position to meet the needs of the patient and the physician. These solutions are readily available and offer high-performance portable options for doctors and other users, as well as a wide range of accessories and spare parts. The company primarily distributes its products through a well-established global network of suppliers and distributors that support the demand for this technology worldwide. It also invests heavily in research and development to maintain and expand its market-leading position in non-invasive surgical treatment technologies for tumors and stones. Another important element for Edap Tms SA is its strong partnerships with leading medical institutions and research facilities to provide the latest opportunities and innovations in medical technology. In summary, Edap Tms SA has a highly successful business model that focuses on providing HIFU and urological solutions for the global market. It has a strong presence in this diverse and emerging field, is well-diversified, and supported by strategic partnerships and distributors. The company offers a wide range of products with innovative technologies and is well-positioned to deliver advanced solutions to medical professionals and patients worldwide in the face of the challenges and demands of the current medical landscape.

Edap Tms keert een dividend van 0 EUR uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Edap Tms of het bedrijf keert geen dividend uit.

De ISIN van Edap Tms is US2683111072.

Het WKN van Edap Tms is 908548.

De ticker van Edap Tms is EDAP.

Binnen de laatste 12 maanden betaalde Edap Tms een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Edap Tms naar verwachting een dividend van 0 EUR betalen.

De dividendrendement van Edap Tms is momenteel .

Edap Tms betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Edap Tms betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 EUR verwacht. Dit komt overeen met een dividendrendement van 0 %.

Edap Tms wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Edap Tms van 7-7-2024 ter hoogte van 0 EUR te ontvangen, moest je het aandeel voor de ex-datum op 7-7-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 7-7-2024.

In het jaar 2023 heeft Edap Tms 0 EUR aan dividenden uitgekeerd.

De dividenden van Edap Tms worden in EUR uitgekeerd.